Jennens I D, Lucas C R, Sandland A M, Maclean H, Hayes K
Department of Medicine, Fairfield Infectious Diseases Hospital, Victoria, Australia.
J Med Virol. 1990 Jan;30(1):42-4. doi: 10.1002/jmv.1890300109.
Nine patients with acquired immunodeficiency syndrome (AIDS) and cytomegalovirus (CMV) retinitis on maintenance therapy with ganciclovir: 9(1,3-dihydroxy-2-propoxymethyl) guanine (DHPG) at high dose (30 mg/kg/week) or low dose (20 mg/kg/week) were tested every 1-2 weeks for CMV isolation from blood, saliva, and urine. Duration of therapy ranged from 1.5 to 12 months (average 5.3 months). During pretreatment and low-dose and high-dose maintenance therapy, CMV was isolated from 48/59 (81%), 90/211 (43%), and 40/290 (14%) of specimens, respectively. Three patients with progressive retinitis had viraemia more frequently than did six patients with stable retinitis, CMV being isolated from 29/47 (62%) and 17/121 (14%) of blood samples, respectively.
9例获得性免疫缺陷综合征（AIDS）且患有巨细胞病毒（CMV）视网膜炎并接受更昔洛韦维持治疗的患者：以高剂量（30mg/kg/周）或低剂量（20mg/kg/周）的9-（1,3-二羟基-2-丙氧甲基）鸟嘌呤（DHPG）治疗，每1-2周检测一次血液、唾液和尿液中的CMV分离情况。治疗持续时间为1.5至12个月（平均5.3个月）。在预处理期间以及低剂量和高剂量维持治疗期间，分别从59份标本中的48份（81%）、211份标本中的90份（43%）和290份标本中的40份（14%）分离出CMV。3例进行性视网膜炎患者的病毒血症发生率高于6例稳定型视网膜炎患者，分别从47份血液样本中的29份（62%）和121份血液样本中的17份（14%）分离出CMV。
